Loading...
•
Sep 30, 2021
Integra LifeSciences Q3 2021 Earnings Report
Reported financial results for the third quarter ending September 30, 2021.
Key Takeaways
Integra LifeSciences reported Q3 2021 revenues of $386.9 million, a 4.5% increase on a reported basis and 6.7% on an organic basis compared to the prior year. GAAP earnings per diluted share were $0.51, compared to $0.38 in the third quarter of 2020, and adjusted earnings per diluted share were $0.86, compared to $0.80 in the prior year.
Revenues of $386.9 million increased 4.5% on a reported basis and 6.7% on an organic basis compared to the prior year.
GAAP earnings per diluted share of $0.51, compared to $0.38 in the third quarter of 2020; adjusted earnings per diluted share of $0.86, compared to $0.80 in the prior year.
Cash flow from operations of $82.8 million increased 18.9% from the prior year.
The Company is raising its full-year 2021 adjusted earnings per share guidance range from $2.98 to $3.05 to a new range of $3.16 to $3.20.
Forward Guidance
The Company is reaffirming its previous full-year 2021 revenue guidance of $1,540 million to $1,550 million, with an expectation to be at the low end of the range. The Company is increasing its full-year 2021 adjusted earnings per share guidance range from $2.98 to $3.05 to a new range of $3.16 to $3.20. Targeting fourth quarter revenue of $403 million, representing reported growth of approximately 3.5% and organic growth of approximately 6.5%. Adjusted earnings per diluted share are expected to be in a range of $0.82 to $0.86.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...